Interacciones de Mitoxantrona

Mitoxantrona tiene 34 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 2; moderadas: 9; leves: 23; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (2)

  • FingolimodinmunosupresorGrave

    When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)] . (etiqueta de Fingolimod, Interacciones medicamentosas)

  • Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (etiqueta de Sofosbuvir y velpatasvir, Interacciones medicamentosas)

Interacciones moderadas (9)

  • CiclosporinainmunosupresorModerada

    Anthracycline Antibiotics High doses of cyclosporine (e.g., at starting intravenous dose of 16 mg/kg/day) may increase the exposure to anthracycline antibiotics (e.g., doxorubicin, mitoxantrone, daunorubicin) in cancer patients. (etiqueta de Ciclosporina, Interacciones medicamentosas)

  • Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (etiqueta de Mitoxantrona, Advertencias)

  • DoxorubicinaModerada

    Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (etiqueta de Mitoxantrona, Advertencias)

  • Eltrombopaginhibidor de OATP1B1Moderada

    …(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (etiqueta de Eltrombopag, Interacciones medicamentosas)

  • HidrocortisonacorticosteroideModerada

    Among 112 patients evaluable for safety on the mitoxantrone injection + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. (etiqueta de Mitoxantrona, Advertencias)

  • LeflunomidainmunosupresorModerada

    For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (etiqueta de Leflunomida, Interacciones medicamentosas)

  • OcrelizumabinmunosupresorModerada

    When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS [see Warnings and Precautions (5.2) ]. (etiqueta de Ocrelizumab, Interacciones medicamentosas)

  • PrednisonacorticosteroideModerada

    In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (etiqueta de Mitoxantrona, Advertencias)

  • TeriflunomidainmunosupresorModerada

    For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (etiqueta de Teriflunomida, Interacciones medicamentosas)

Menciones leves (23)

  • Azelastina y fluticasonaantihistamínicoLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • BeclometasonacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • BetametasonacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • BudesonidacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • Budesonida y formoterolcorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • CiclesonidacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • CitarabinaantimetabolitoLeve

    In first-line comparative trials of mitoxantrone injection + cytarabine vs. daunorubicin + cytarabine in adult patients with previously untreated ANLL, therapy was associated with congestive heart failure in 6.5% of patients on each arm. (etiqueta de Mitoxantrona, Advertencias)

  • ClobetasolcorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • DeflazacortcorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • DesonidacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • DexametasonacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • FludrocortisonacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • FlunisolidacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • FluocinonidacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • FluticasonacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • Fluticasona y salmeterolcorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • HalobetasolcorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • MetilprednisolonacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • MometasonacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • NatalizumabinmunosupresorLeve

    • Prior treatment with an immunosuppressant (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil). (etiqueta de Natalizumab, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • PrednisolonacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • TriamcinolonacorticosteroideLeve

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

Compruebe Mitoxantrona frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.